Erlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma
Publication in refereed journal

Times Cited
Altmetrics Information

Other information
AbstractHead and neck squamous cell carcinoma (HNSCC) lacks predictive biomarkers for drug responses. By targeted sequencing, we identified two MAPK1 mutations in recurrent HNSCC, MAPK1p.D321N, and p.R135K. We previously reported an exceptional erlotinib responder with MAPK1p.E322K. Here, by in silico and drug studies, we determined functions of these two recurrence-associated MAPK1 mutations. Residues D321, R135, and E322 are in 3D proximity. MAPK1p.D321N drives marked in vivo erlotinib sensitivity, while p.R135K’s effect is moderate.
All Author(s) ListHoi-Lam NGAN, Peony Hiu Yan POON, Yu-Xiong SU, Jason Ying Kuen CHAN, Kwok-Wai LO, Chun Kit YEUNG, Yuchen LIU, Eileen WONG, Hui LI, Chin Wang LAU, Wenying PIAO, Vivian Wai Yan LUI
Journal namenpj Genomic Medicine,npj Genomic Medicine
Volume Number5
Issue Number1
PublisherNature Publishing Group
Article number17
LanguagesEnglish-United Kingdom

Last updated on 2021-23-09 at 23:46